Insider plans sale of 1,500 HCA Healthcare shares

HCA Healthcare, Inc. shareholder plans Rule 144 sale of shares A shareholder has filed a notice of intent to sell 1,500 shares of HCA Healthcare common stock through Merrill Lynch on the NYSE.

Rhea-AI Filing Summary

HCA Healthcare, Inc. shareholder plans Rule 144 sale of shares

A shareholder has filed a notice of intent to sell 1,500 shares of HCA Healthcare common stock through Merrill Lynch on the NYSE. The filing lists an aggregate market value of $747,135.15 and indicates an approximate sale date of February 3, 2026.

The shares were acquired on April 29, 2021 through the exercise of a stock appreciation right from HCA Healthcare, described as a compensatory payment. The notice states that the person signing does not know of any undisclosed material adverse information about HCA Healthcare’s current or prospective operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the HCA (HCA Healthcare) Form 144 filing disclose?

The Form 144 discloses a planned sale of HCA Healthcare shares under Rule 144. A shareholder intends to sell 1,500 common shares on the NYSE through Merrill Lynch, with an indicated aggregate market value of $747,135.15 and an approximate sale date of February 3, 2026.

How many HCA common shares are planned to be sold under this Form 144?

The filing covers 1,500 HCA Healthcare common shares. These shares are listed in the securities information table as the number of units to be sold, with trading expected on the NYSE via Merrill Lynch at an aggregate market value of $747,135.15.

When and how were the HCA shares in this Form 144 acquired?

The 1,500 HCA shares were acquired on April 29, 2021. The filing states they came from the exercise of a stock appreciation right from HCA Healthcare, described as a compensatory payment, meaning they were received as part of compensation rather than a cash purchase.

What is the approximate sale date for the HCA shares in this Form 144?

The filing lists an approximate sale date of February 3, 2026. This date appears in the securities information table and indicates when the shareholder expects to begin selling the 1,500 HCA common shares on the NYSE under Rule 144.

What aggregate market value is associated with the HCA shares to be sold?

The planned sale is tied to an aggregate market value of $747,135.15. This figure is disclosed alongside the 1,500 HCA Healthcare common shares to be sold, reflecting the total market value used in the Form 144 notice for this planned transaction.

What representation does the HCA shareholder make in this Form 144?

The shareholder represents they do not know any undisclosed material adverse information. By signing the notice, they affirm that they are unaware of negative information about HCA Healthcare’s current or prospective operations that has not already been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 04:36 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001632835
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	HCA Healthcare, Inc.
SEC File Number	001-11239
Address of Issuer	One Park Plaza Nashville TENNESSEE 37203
Phone	6153449551
Name of Person for Whose Account the Securities are To Be Sold	MICHAEL S CUFFE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 3455 Peachtree Road NE STE 1000 Atlanta GA 30326	1500	747135.15	228193900	02/03/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/29/2021	Exercise of a Stock Appreciation Right	HCA Healthcare, Inc.			1500	04/29/2021	Compensatory Payment

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Michael S. Cuffe
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)